IAP antagonists induce anti-tumor immunity in multiple myeloma

The cellular inhibitor of apoptosis cIAP1 and −2 are amplified in about 3% of cancers, and were identified in multiple malignancies as potential therapeutic targets due to their role in evasion of apoptosis. Consequently, small molecule IAP antagonists, like LCL161, have entered clinical trials for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Chesi, Marta, Mirza, Noweeda N., Garbitt, Victoria M., Sharik, Meaghen E., Dueck, Amylou C., Asmann, Yan W., Akhmetzyanova, Ilseyar, Kosiorek, Heidi E., Calcinotto, Arianna, Riggs, Daniel L., Keane, Niamh, Ahmann, Greg J., Morrison, Kevin M., Fonseca, Rafael, Lacy, Martha Q., Dingli, David, Kumar, Shaji K., Ailawadhi, Sikander, Dispenzieri, Angela, Buadi, Francis, Gertz, Morie A., Reeder, Craig B., Lin, Yi, Chanan-Khan, Asher Alban, Stewart, A. Keith, Fooksman, David, Bergsagel, P. Leif
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5515246/
https://ncbi.nlm.nih.gov/pubmed/27841872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4229
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados